EGFR and non-small cell lung carcinoma: Currently, EGFR mutation testing is considered as a prerequisite for the management of patients with advanced or metastatic NSCLC as it greatly helps for selecting patients for EGFR-targeted therapies, clonal evolution and resistance to treatment monitoring.